Topics
Innovation
Laser
Medical
Practice
Research
Surgical
Training
Considerations for addressing patients’ quality of life without further compromising quality of vision.
View Issue
In This Issue
Arsham Sheybani, MD
A review of progression analysis and testing algorithms and a look ahead at future technologies.
Astrid Werner, MD
The iridotomy dilemma.
Devesh K. Varma, MD, FRCSC; Shan C. Lin, MD; James Liu, MD; and Kelly W. Muir, MD, MHSc
Phase 3 clinical trials led to the FDA’s approval of a fixed-combination agent and an intracameral drug implant.
Michael Izzo, MD, and Reena A. Garg, MD
Getting it right and leaving a positive impression.
Richie Kahn, MPH
When life goes off script, pick up a pen and write a new one.
Rikki Enzor, MD, PhD
An overview of resourceful approaches to glaucoma care in resource-limited contexts.
Patrick Commiskey, MD; Melanie Scheive; David Rooney, MD; and Manjool Shah, MD
Although rare, this complication can be challenging for both the patient and the surgeon.
Monica K. Ertel, MD; Cara E. Capitena Young, MD; and Sarah H. Van Tassel, MD
Understanding the mechanism of IOP elevation after vitreoretinal surgery helps guide the best management approach.
Steve Charles, MD, FACS, FICS, and Adam Pflugrath, MD
A practice-based survey revealed issues with patient accessibility.
Nikola Ragusa, MD
What factors must be considered when evaluating the evolving lens options for use in glaucomatous eyes?
Ticiana De Francesco, MD; John Liu, MD; and Iqbal Ike K. Ahmed, MD, FRCSC
Many surgeons have avoided implanting multifocal IOLs in patients with glaucoma out of concern that these lenses will reduce contrast sensitivity, but is this dogma outdated?
Brian M. Shafer, MD
What are the keys to delivering on patient expectations of refractive cataract surgery in glaucomatous eyes?
Michael D. Greenwood, MD
How can we best marry the benefits of IOL technology and glaucoma surgery?
I. Paul Singh, MD
Subscribe
Stay up to date all on all things Glaucoma by signing up to receive our print publication or subscribe to our email alerts.